Autor:
Koefoed, K.
Steinaa, Lucilla
Soderberg, J.N.
Kjaer, I.
Jacobsen, H.J.
Meijer, P.-J.
Haurum, J.S.
Jensen, A.
Kragh, M.
Andersen, P.S.
Pedersen, M.W.
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low...
Enlace original:
https://cgspace.cgiar.org/handle/10568/35344
Koefoed, K.
,
Steinaa, Lucilla
,
Soderberg, J.N.
,
Kjaer, I.
,
Jacobsen, H.J.
,
Meijer, P.-J.
,
Haurum, J.S.
,
Jensen, A.
,
Kragh, M.
,
Andersen, P.S.
,
Pedersen, M.W.
,
[Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor]
,
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor